Research Achievements - Other -
-
The challenge of achieving treatment-free remission for chronic myeloid leukemia
TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 67 ( 2 ) 158 - 164 2026
<p>While tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis for patients with chronic myeloid leukemia (CML), lifelong therapy presents challenges such as long-term toxicities and financial burden. Consequently, treatment-free remission (TFR) has become a primary therapeutic goal, with the aim of safely discontinuing TKIs while maintaining remission and enhancing patient quality of life (QoL). The feasibility and safety of TFR have been established through numerous clinical trials worldwide. The large-scale J-SKI observational study confirmed a 5-year TFR rate of 65.2% and demonstrated its safety in clinical practice. A sustained period of deep molecular response (DMR) is the most critical predictive factor for a successful TFR attempt. Current challenges include TKI withdrawal syndrome, the success of second TFR attempts, and the rare risk of blast crisis during TFR. Future strategies aim to increase TFR eligibility by achieving higher DMR rates with newer agents.</p>
-
The impact of NR1I2 gene polymorphism and body weight on asciminib pharmacokinetics in patients with chronic myeloid leukemia
Naoto Takahashi, Yumiko Akamine, Masatomo Miura
BLOOD 146 2025.11
Summary of the papers read (international conference)
-
Kumagai Takuya, Saito Masaya, Sato Takahiko, Inoue Junichi, Ishikawa Norihisa, Ono Tsuyoshi, Kono Michihiro, Takahashi Naoto
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 1933 - 1940 2025
<p>We herein report a case of cutaneous squamous cell carcinoma (SCC) characterized by paraneoplastic hypercalcemia-leukocytosis syndrome. The patient presented with systemic symptoms, including anorexia, a fever, and a tumoral lesion on the upper arm. Laboratory test results revealed hypercalcemia and leukocytosis. A tissue biopsy confirmed SCC, and further investigation revealed elevated parathyroid hormone-related protein (PTHrP) and granulocyte-colony stimulating factor (G-CSF) levels. Immunostaining demonstrated G-CSF production by the tumor cells. Radiation therapy was administered, which improved leukocytosis and decreased G-CSF and PTHrP levels. Through a case report and literature review, we explored the clinical characteristics of tumors that produce G-CSF and PTHrP. </p>
-
Fujishima Takashi, Kobayashi Takahiro, Kobayashi Isuzu, Kitadate Akihiro, Kameoka Yoshihiro, Takahashi Naoto
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 3020 - 3026 2025
<p>We herein present the case of a 73-year-old man with IgM multiple myeloma (IgM-MM) and t(11;14). The tumor cells showed a small lymphoplasmacytic morphology and dim expression of CD38 and CD138. The MYD 88<sup>L265P</sup> mutation was found to be negative. After plasma exchange, bortezomib and dexamethasone treatments were refractory. Subsequent daratumumab, lenalidomide, and dexamethasone therapy failed to respond despite the standard therapy for non-IgM MM. Subsequently, pomalidomide, cyclophosphamide, and dexamethasone therapies demonstrated a good response, and a stringent complete response was therefore achieved. This case highlights the need for different treatment strategies for IgM-MM compared with non-IgM-MM because the biological features of IgM-MM and non-IgM-MM are different. </p>
-
Ikeda Sho, Kobayashi Takahiro, Kitadate Akihiro, Yamashita Takaya, Watanabe Atsushi, Fujishima Naohito, Yoshioka Tomoko, Kume Masaaki, Kameoka Yoshihiro, Kitabayashi Atsushi, Kuroki Jun, Takahashi Naoto
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 2025
<p><b>Objective </b>In the real-world clinical setting of transplant-eligible patients with multiple myeloma (MM), a certain proportion of patients switch from induction therapy to other regimens because of insufficient response or adverse events. However, the prognostic benefits of these changes remain unclear. This retrospective study investigated the impact of pre-transplant induction therapy switches on the prognosis. </p><p><b>Methods </b>We analyzed the treatment course, patient background, risk classification, and post-transplantation event-free survival (EFS) of 35 patients who achieved partial response (PR) or better with triplet therapy and underwent autologous stem cell transplantation (ASCT) at our institution between January 2017 and July 2023. </p><p><b>Results </b>Induction therapy included VRd therapy in 11 patients and switching therapy in 20 patients (7 due to intolerance and 13 due to insufficient treatment effects). Among the 13 patients who switched treatment due to insufficient treatment effects, 10 showed an improved response, leading to a trend towards a better EFS. Nevertheless, high-risk chromosomal abnormalities, particularly t(4;14), were associated with a significantly poorer EFS, regardless of the treatment received. </p><p><b>Conclusion </b>Even with a response-guided induction treatment switch, maintaining long-term remission after ASCT in high-risk patients remains challenging. A careful risk assessment using fluorescence <i>in situ</i> hybridization or a genomic analysis may improve the prognosis of patients with MM in the future. </p>
-
Outpatient treatment of CML using TDM in collaboration with physicians and pharmacists
ABUMIYA Maiko, TAKAHASHI Naoto, MIURA Masatomo
日本血液学会学術集会抄録(Web) 87th 2025
-
Pharmacokinetics of asciminib in patients with chronic myeloid leukemia
TAKAHASHI Naoto, MIURA Masatomo
日本血液学会学術集会抄録(Web) 87th 2025
-
LINC00887はHDAC3との結合を介して多発性骨髄腫細胞の薬剤耐性を誘導する
長田 直希, 松岡 紗恵, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 1 2024.10
-
SETD7はt(11;14)陽性多発性骨髄腫に対する新たな治療標的分子となる
松岡 紗恵, 長田 直希, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 4 2024.10
-
LINC00887はHDAC3との結合を介して多発性骨髄腫細胞の薬剤耐性を誘導する
長田 直希, 松岡 紗恵, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 1 2024.10
-
SETD7はt(11;14)陽性多発性骨髄腫に対する新たな治療標的分子となる
松岡 紗恵, 長田 直希, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 4 2024.10
-
TFR後の晩期再発は免疫の調節不全を背景にしている
藤岡 優樹, 植木 重治, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 5 2024.10
-
小児白血病におけるチロシンキナーゼ阻害剤の薬物血中濃度モニタリング
田村 真一, 内藤 優樹, 友安 千紘, 矢野 未央, 三浦 昌朋, 高橋 直人, 石田 宏之
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 P1 - 6 2024.10
-
7. Progress in the Treatment of CML
Takahashi Naoto
Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine ) 113 ( 9 ) 1732 - 1737 2024.09
-
7. Progress in the Treatment of CML
Takahashi Naoto
Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine ) 113 ( Suppl ) 120a - 120a 2024.02
-
Successful cord blood transplantation for refractory gamma-delta hepatosplenic T-cell lymphoma developed during treatment of Crohn's disease
SAITO Akihito, NARA Miho, FUJISHIMA Takashi, KUROKI Wataru, YAMASHITA Takaya, KOBAYASHI Takahiro, IKEDA Sho, KITADATE Akihiro, KAMEOKA Yoshihiro, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 65 ( 1 ) 41 - 46 2024
<p>The patient was a 21-year-old man who had been diagnosed with Crohn's disease and received infliximab and azathioprine six years earlier. He was admitted with fever and fatigue. Peripheral blood examination showed LDH 2,473 U/<i>l</i> and thrombocytopenia, and contrast-enhanced computed tomography (CT) showed hepatosplenomegaly. Bone marrow biopsy and liver biopsy showed CD4+CD56+TCR<i>γδ</i>+CD8<sup>−</sup> atypical cells, leading to a diagnosis of hepatosplenic T-cell lymphoma (HSTCL). The patient was refractory to CHOP and DA-EPOCH, and therefore received cord blood transplantation with myeloablative conditioning. CT showed reduced in hepatosplenomegaly and peripheral blood examination showed LDH 165 U/<i>l</i> and plt 180,000/µ<i>l</i>, so the patient was discharged on day117. HSTCL is a tumor of immature <i>γδ</i>T cells with a V<i>δ</i>1 mutation in the spleen, and immunodeficiency has been implicated in its pathogenesis. Patients with inflammatory bowel disease treated with azathioprine are known to have an increased risk of lymphoproliferative disease. In this case, use of immunosuppressive drugs for Crohn's disease may have caused malignant transformation of <i>γδ</i> cells in the intestinal epithelium. Although the patient was refractory to chemotherapy, he was able to achieve remission with early cord blood transplantation and long-term survival is expected.</p>
-
Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto
Cancer Chemotherapy and Pharmacology ( Springer Nature ) 2024
-
t(4;14)陽性多発性骨髄腫に対するMMSET阻害剤
松岡 紗恵, 菊池 次郎, 長田 直希, 窪田 浩一, 喜久里 貢, 小山 裕雄, 菊地 正樹, 安井 寛, 池田 翔, 高橋 直人, 梅原 崇史, 仲宗根 秀樹, 古川 雄祐
日本血液学会学術集会 ( (一社)日本血液学会 ) 85回 44 - 44 2023.10
-
AMLのVEN/AZA治療におけるベネトクラクスの血中濃度と好中球減少症との関連
小林 敬宏, 佐藤 保奈実, 三浦 昌朋, 福司 弥生, 藤田 菜々子, 黒木 航, 伊藤 史子, 手島 和暁, 渡部 敦, 藤島 直仁, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 85回 377 - 377 2023.10
-
Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation.
Kazuaki Teshima, Sho Ikeda, Ko Abe, Masahiro Yamada, Naoto Takahashi
Cureus 15 ( 7 ) e42215 2023.07
A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.
-
長田 直希, 菊池 次郎, 安井 寛, 池田 翔, 松岡 紗恵, 高橋 直人, 古川 雄祐
International Journal of Myeloma ( (一社)日本骨髄腫学会 ) 13 ( 3 ) 136 - 136 2023.05
-
Refractory esophageal stricture of esophageal mucous membrane pemphigoid after allogeneic hematopoietic stem cell transplantation
FUJITA Nanako, YAMASHITA Takaya, ABE Fumito, NARA Miho, YOSHIOKA Tomoko, KOGA Hiroshi, ISHII Norito, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 64 ( 2 ) 107 - 112 2023
<p>Haploidentical allogeneic hematopoietic stem cell transplantation from her brother was performed on a 41-year-old lady with no prior history of pemphigoid to treat recurrent AML. On day 59 following transplantation, she experienced esophageal stenosis. During immunosuppressive therapy for graft vs. host disease, this condition was controlled with periodic esophageal dilatation (GVHD). Her esophageal stricture, which required periodic dilatation, grew worse after she stopped immunosuppressive therapy because of recurrent AML. The esophageal mucosa was easily hemorrhagic and desquamative. Histologic analysis revealed that the squamous cell layers had been divided. Indirect immunofluorescence was negative for IgG and positive for IgA on the epidermal layers, while direct immunofluorescence showed a linear deposition of IgG on the basement membrane zone. It was determined through immunoblotting utilizing recombinant protein of BP180 C-terminal domain that both IgG and IgA antibodies were present, supporting the diagnosis of mucous membrane pemphigoid with anti-BP180. After allogeneic transplantation, basal epidermal cell destruction by GVHD may result in autoimmune blistering disorders, which expose basement membrane proteins and antigen presentation. A similar mechanism could apply to our situation. For rare GVHD cases, a thorough histological diagnosis is required.</p>
-
c-FOS mediates IMiDs resistance acting as a co-activator of IKZF1-target genes in multiple myeloma.
長田直希, 菊池次郎, 松岡紗恵, 安井寛, 池田翔, 高橋直人, 仲宗根秀樹, 古川雄祐
日本癌学会学術総会抄録集(Web) 82nd 2023
-
KUROKI Wataru, KOBAYASHI Takahiro, UMAKOSHI Michinobu, KITADATE Akihiro, IMAIZUMI Chihiro, SAITO Masaya, KOBAYASHI Isuzu, FUJISHIMA Masumi, FUJISHIMA Naohito, YOSHIOKA Tomoko, GOTO Akiteru, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 63 ( 6 ) 523 - 529 2022
<p>Atraumatic splenic rupture (ASR) is a rare but fatal complication of malignant lymphoma. However, only one case of intravascular large B-cell lymphoma (IVLBCL)-related ASR (IVLBCL-ASR) has previously been reported, and the mechanism of IVLBCL-ASR is unknown. We present the case of a 78-year-old man who died unexpectedly and was diagnosed with IVLBCL-ASR pathologically by autopsy. A massive intraperitoneal hemorrhage and four lacerations on the splenic surface were discovered during the autopsy. CD20-positive lymphoma cells that infiltrated into small vessels were highly concentrated in the center of the spleen and were only slightly distributed in the lacerations on the splenic surface. Therefore, increased intrasplenic pressure due to lymphoma cell proliferation was identified as the cause of ASR. The patient had undergone <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) for tongue cancer evaluation 3 months earlier, and positive uptake was found in the right adrenal gland, where lymphoma cell infiltration was confirmed by the autopsy. Our findings suggest that clinicians should be aware that the advanced stage of IVLBCL can cause fatal ASR via increased intrasplenic pressure. Therefore, early diagnosis and early treatment intervention are desirable to prevent the onset of IVLBCL-ASR, and <sup>18</sup>F-FDG PET/CT is useful for the early diagnosis of IVLBCL.</p>
-
Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH
FUJISHIMA Takashi, KAWABATA Yoshinari, MICHISHITA Yoshihiro, KITABAYASHI Atushi, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 63 ( 10 ) 1386 - 1391 2022
<p>Plasmablastic lymphoma (PBL) is a rare variant of diffuse large B-cell lymphoma that is frequently associated with HIV infection or other immunodeficiencies. We present a case of HIV-negative primary testicular PBL with long-term complete remission (CR) and successful treatment with bortezomib in combination with EPOCH (V-EPOCH). Because of rapidly increasing right testicular swelling, an 86-year-old man without immunodeficiencies was admitted to our hospital. Following that, a right high orchiectomy was performed. Histopathological and immunohistochemical analyses revealed diffuse infiltration of plasmablastic lymphocytes, which were positive for CD38, CD138, CD56, MUM1, lambda, EBER, and MYC respectively, but negative for CD20. The MIB-1 index was 90%. FDG abnormal uptake was discovered on PET/CT at systemic lymph nodes. There was no abnormal cell infiltration in either the bone marrow or cerebral spinal fluid. He was diagnosed with PBL, clinical-stage IIIE-A, IPI high-intermediate risk. He achieved durable CR more than 30 months after the diagnosis after six courses of V-EPOCH, followed by intrathecal prophylaxis (IT) and adjuvant radiation therapy (total 30 Gy). Although PBL shows an aggressive clinical course and poor prognosis, adequate therapeutic approaches for PBL have not been established due to the rarity of this disease. According to our findings, V-EPOCH combined with IT and adjuvant radiotherapy appeared to be feasible and effective as a frontline treatment for elderly patients with primary testicular PBL.</p>
-
R-MPV療法を施行した中枢神経原発悪性リンパ腫の有効性と安全性の解析(The safety and efficacy of R-MPV therapy for untreated primary CNS lymphoma(PCNSL))
亀岡 吉弘, 阿部 滉, 山田 雅浩, 渡部 敦, 茂木 睦仁, 久米 正晃, 波多野 善明, 小笠原 仁, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS1 - 4 2021.09
-
ボスチニブ治療における血清クレアチニン値はボスチニブ血中トラフ濃度とSLC22A2遺伝子多型に影響される(Effect of SLC22A2 SNP and bosutinib concentrations on serum creatinine in patients taking bosutinib)
鐙屋 舞子, 高橋 直人, 高橋 さおり, 吉岡 智子, 亀岡 吉弘, 三浦 昌朋
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS2 - 5 2021.09
-
慢性骨髄性白血病急性転化におけるクローン進化および遺伝子異常と予後の解析(Clonal evolution and clinical impact of genetic lesions in blast crisis of chronic myeloid leukemia)
越智 陽太郎, 吉田 健一, 南谷 泰仁, 佐々木 光, 三谷 絹子, 細谷 紀子, 平本 展大, 石川 隆之, 大屋敷 一馬, 高橋 直人, 高久 智生, 土屋 俊, 兼村 信宏, 中村 信彦, 上田 恭典, 吉原 哲, 塩澤 裕介, 趙 蘭英, 竹田 淳恵, 綿谷 陽作, 奥田 瑠璃花, 牧島 秀樹, 白石 友一, 千葉 健一, 田中 洋子, 真田 昌, 高折 晃史, 宮野 悟, Shih Lee-Yung, 小川 誠司
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS1 - 1 2021.09
-
慢性骨髄性白血病急性転化のクローン進化および遺伝子異常と予後
越智 陽太郎, 吉田 健一, 南谷 泰仁, 佐々木 光, 三谷 絹子, 細谷 紀子, 石川 隆之, 大屋敷 一馬, 高橋 直人, 塩澤 裕介, 牧島 秀樹, 白石 友一, 真田 昌, 高折 晃史, 宮野 悟, 小川 誠司
日本癌学会総会記事 ( (一社)日本癌学会 ) 80回 [E14 - 1] 2021.09
-
再発難治性ホジキンリンパ腫に対する免疫チェックポイント阻害薬治療の後方視的解析(Retrospective analysis of ICI therapy for relapsed or refractory classical Hodgkin's lymphoma: THF26)
前田 峻大, 小宅 達郎, 久保 恒明, 高畑 武功, 玉井 佳子, 亀岡 吉弘, 高橋 直人, 宮入 泰郎, 村井 一範, 下瀬川 健二, 吉田 こず恵, 菅原 健, 猪倉 恭子, 福原 規子, 張替 秀郎, 佐藤 諒, 石澤 賢一, 田嶋 克史, 齊藤 宗一, 深津 真彦, 池添 隆之, 角田 三郎, 神林 裕行, 三田 正行, 森 甚一, 古和田 周吾, 伊藤 薫樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS2 - 2 2021.09
-
成人初期前駆T細胞性急性リンパ性白血病の臨床的特徴と予後に関する後方視的研究 THF-24(Clinical features and prognosis of adult early T-cell precursor acute lymphoblastic leukemia: THF-24)
古川 瑛次郎, 大西 康, 遠宮 靖雄, 原崎 頼子, 深津 真彦, 池添 隆之, 亀岡 吉弘, 高橋 直人, 八田 俊介, 勝岡 優奈, 濱田 宏之, 村井 一範, 小宅 達郎, 伊藤 薫樹, 甲斐 龍幸, 助川 真純, 中嶌 真治, 柳谷 稜, 石澤 賢一, 山口 公平, 高橋 太郎, 張替 秀郎
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS3 - 5 2021.09
-
濾胞性リンパ腫におけるリツキシマブ維持療法の長期生存 東北血液フォーラム前向き多施設共同研究結果(Long-term survival in patients with follicular lymphoma following Rituximab maintenance in THF-19)
大本 英次郎, 妻沼 りこ, 熊谷 裕昭, 相澤 桂子, 吉田 こず恵, 池田 和彦, 亀岡 吉弘, 石澤 賢一, 張替 秀郎, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 BPA - 6 2021.09
-
Kobayashi T.
International Journal of Hematology ( International Journal of Hematology ) 2021
Domestic Co-author
-
NOGUCHI Shinsuke, SAITOH Hirobumi, SASAKI Hideto, KAMATA Shuichi, ENOMOTO Katsuhiko, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 62 ( 5 ) 341 - 345 2021
<p>Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin's lymphoma that mostly affects women. Here, we report a case of primary breast DLBCL that affected an older man without any autoimmune disease or drug-related female hormones. The patient was a 65-year-old man whose chief complaints were gradually-increasing lump in the right chest and swelling of the right axillary lymph nodes. He was diagnosed with malignant lymphoma through a needle biopsy on suspicion of right breast cancer with right axillary lymph node metastasis. Since the histological type could not be confirmed, right breast mass resection was performed. The patient was referred to our department for treatment because of the diagnoses of primary breast DLBCL, germinal center B-cell type (Hans classification), and clinical stage IIA. In addition to the six courses of R-CHOP therapy, intrathecal injections were used in combination to prevent CNS infiltration. He has been in complete remission for 5 years. Although rare, breast lymphoma can also occur in men; therefore, early histological diagnosis and response to CNS recurrence prevention are important.</p>
-
髄外疾患はヒアルロナン誘導同種親和性骨髄腫細胞-細胞相互作用に由来する【JST・京大機械翻訳】|||
菊池次郎, 小玉信之, 小玉信之, 竹下昌孝, 竹下昌孝, 比島智子, 比島智子, 池田翔, 小林敬宏, 黒田芳明, 内山倫宏, 長田直希, 小山大輔, BOGEN Bjarne, 安井寛, 高橋直人, 三輪哲義, 三輪哲義
日本血液学会学術集会抄録(Web) ( (一社)日本血液学会 ) 83rd ( 2 ) OS2 - 1 2021
-
Hino M.
International Journal of Hematology ( International Journal of Hematology ) 112 ( 1 ) 24 - 32 2020.07 [Refereed]
Domestic Co-author
-
Ko T.K.
Blood ( Blood ) 135 ( 26 ) 2337 - 2353 2020.06 [Refereed]
International Co-author
-
好酸球増多疾患・好酸球性肺炎 著明な組織内シャルコー・ライデン結晶を認めた好酸球増多症候群患者
福地 峰世, 植木 重治, 山本 洋平, 奈良 美保, 今野 泰典, 面川 歩, 嵯峨 知生, 守時 由起, 大森 泰文, 高橋 直人, 廣川 誠
アレルギー ( (一社)日本アレルギー学会 ) 68 ( 4-5 ) 529 - 529 2019.05
-
Guo YM, Abumiya M, Yamashita T, Ubukawa K, Takahashi N
Clinical pharmacology in drug development 8 ( 3 ) 411 - 412 2019.04
-
Ogawa M, Yokoyama K, Hirano M, Jimbo K, Ochi K, Kawamata T, Ohno N, Shimizu E, Yokoyama N, Yamaguchi R, Imoto S, Uchimaru K, Takahashi N, Miyano S, Imai Y, Tojo A
British journal of haematology 183 ( 5 ) 842 - 845 2018.12
-
CML患者のボスチニブ血中濃度におけるNR1/2, CYP3A4およびABCトランスポーター遺伝子多型の影響(Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the concentrations of bosutinib)
鐙屋 舞子, 三田 亜紀子, 吉岡 智子, 亀岡 吉弘, 高橋 直人, 三浦 昌朋
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1532 - 1532 2018.09
-
INCREASED MEAN PLATELET VOLUME (MPV) AS A POTENTIAL PREDICTOR OF THROMBOPOIETIC RECOVERY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHEMOTHERAPY
Yuko Kikuchi, Ayako Naganuma, Kana Haseyama, Kyoko Ono, Takeshi Kobayashi, Noriko Kobayashi, Ayumi Omokawa, Tomoo Saga, Shigeharu Ueki, Naoto Takahashi, Hironobu Shimizu, Makoto Hirokawa
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY ( WILEY ) 40 68 - 69 2018.09
Summary of the papers read (international conference)
-
秋田県内の多施設調査による骨髄異形成症候群に対するアザシチジンの使用状況と安全性/有効性に関する検討(Azacitidine safety and efficacy in Myelodysplastic syndrome: A multicenter survey in Akita)
渡部 敦, 吉岡 智子, 伊藤 史子, 池田 翔, 郭 永梅, 奈良 美保, 藤島 眞澄, 藤島 直仁, 市川 善一, 中山 豊, 川端 良成, 北林 淳, 桑山 明久, 小笠原 仁, 井上 武, 茂木 睦仁, 仁村 隆, 三田 亜紀子, 道下 吉広, 波多野 善明, 伊藤 貢, 黒木 淳, 手島 和明, 大八木 秀明, 久米 正晃, 野口 晋佐, 鵜生川 久美, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1780 - 1780 2018.09
-
成人特発性血小板減少症におけるIGHV4-28/IGHJ4再構成由来IgG型B細胞抗原受容体の高発現(Overexpression of the rearranged IGHV4-28//IGHJ4 gene-derived IgG B-cell receptors in adult ITP)
藤島 直仁, 富樫 賢, 長谷川 諒, 渡部 健, 嵯峨 亜希子, 面川 歩, 嵯峨 知生, 植木 重治, 高橋 直人, 北浦 一孝, 鈴木 隆二, 廣川 誠
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1579 - 1579 2018.09
-
腸炎を契機に発症した横紋筋融解に伴う急性腎障害
齋藤 雅也, 渡邊 春佳, 阿部 史人, 池田 翔, 奈良 瑞穂, 鵜生川 久美, 佐藤 隆太, 奥山 慎, 亀岡 吉弘, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 60 ( 6 ) 902 - 902 2018.08
-
[Chronic myeloid leukemia: state-of-the-art management].
Takahashi N
[Rinsho ketsueki] The Japanese journal of clinical hematology ( The Japanese Society of Hematology ) 59 ( 6 ) 747 - 754 2018.06
<p>Treatment-free remission leading to a sustained deep molecular response (DMR) following the discontinuation of tyrosine kinase inhibitor (TKI) is a therapeutic goal in patients with chronic myeloid leukemia chronic phase (CML-CP). In 2017, discontinuing TKI treatment at the outside of clinical trials was recommended for the first time by National Comprehensive Cancer Network guidelines. The criteria for TKI discontinuation include at least 3 years of TKI therapy, a stable DMR for ≥2 years, and monthly molecular monitoring during the first 6 months following discontinuation of treatment. Moreover, discontinuing TKI treatment at the outset of clinical trials may soon be recommended by the Japanese CML guidelines. Thus, achieving a sustained DMR is the current focus of research in CML-CP patients without a history of TKI resistance.</p>
-
骨髄腫微小環境で発現上昇する解糖系遺伝子群の治療標的としての可能性
池田翔, 北舘明宏, 北舘明宏, 阿部史人, 小林敬宏, 高橋直人, 田川博之
International Journal of Myeloma (Web) 8 ( 2 ) 92 - 92 2018.05
-
治療への基礎的アプローチ 骨髄腫微小環境で発現上昇する解糖系遺伝子群の治療標的としての可能性
池田 翔, 北舘 明宏, 阿部 史人, 小林 敬宏, 高橋 直人, 田川 博之
International Journal of Myeloma ( 日本骨髄腫学会 ) 8 ( 2 ) 92 - 92 2018.05
-
High-Throughput Sequencing of IgG B-Cell Receptors Reveals the Frequent Usage of the Rearranged IGHV4-28//IGHJ4 Gene in Primary Immune Thrombocytopenia in Adults
Naohito Fujishima, Masaru Togashi, Ryo Hasegawa, Ken Watanabe, Akiko Saga, Ayumi Omokawa, Tomoo Saga, Shigeharu Ueki, Naoto Takahashi, Kazutaka Kitaura, Ryuji Suzuki, Makoto Hirokawa
BLOOD ( AMER SOC HEMATOLOGY ) 130 2017.12
Summary of the papers read (international conference)
0
-
Histone Deacetylase Inhibitors Downregulate CCR4 Expression and Decrease Mogamulizumab Efficacy in CCR4-Positive Mature T-Cell Lymphomas
Kitadate Akihiro, Ikeda Sho, Abe Fumito, Takahashi Naoto, Shimizu Norio, Matsue Kosei, Tagawa Hiroyuki
BLOOD 130 2017.12
-
Hypoxia-Inducible KDM3A Addiction in Multiple Myeloma
Ikeda Sho, Kitadate Akihiro, Abe Fumito, Takahashi Naoto, Tagawa Hiroyuki
BLOOD 130 2017.12
-
T細胞リンパ腫においてHDAC阻害剤はCCR4発現を減少させモガムリズマブの作用を減弱させる
北舘 明宏, 池田 翔, 阿部 史人, 手島 和暁, 高橋 直人, 末永 孝生, 田川 博之
日本癌学会総会記事 ( 日本癌学会 ) 76回 E - 2025 2017.09
-
低酸素環境における骨髄腫細胞の生存はH3K9脱メチル化酵素KDM3Aに依存する
池田 翔, 北舘 明宏, 阿部 史人, 高橋 直人, 田川 博之
日本癌学会総会記事 ( 日本癌学会 ) 76回 J - 3036 2017.09
-
悪性リンパ腫におけるイノシトールリン脂質プロファイル
阿部 史人, 中西 広樹, 北舘 明宏, 池田 翔, 亀岡 吉弘, 高橋 直人, 佐々木 雄彦, 田川 博之
日本癌学会総会記事 ( 日本癌学会 ) 76回 P - 2236 2017.09
-
早期LCDDに対してVRD療法が奏功した一例
齋藤 綾乃, 池田 翔, 伊藤 香里, 阿部 史人, 奈良 瑞穂, 奥山 慎, 涌井 秀樹, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 59 ( 6 ) 893 - 893 2017.09
-
The clinical efficacy of tyrosine kinase inhibitors for patients with Ph-positive ALL
75 ( 3 ) 287 - 293 2017.09
-
CPC解説(第97回) 両肺に多発肺腫瘤を形成した若年成人発症菌状息肉症の一剖検例
伊藤 行信, 吉田 誠, 馬越 通信, 前田 大地, 高橋 啓, 郭 永梅, 高橋 直人, 後藤 明輝
病理と臨床 ( (株)文光堂 ) 35 ( 8 ) 759 - 765 2017.08
-
虚血性持続勃起症(Priapism)を契機に発見された急性骨髄性白血病とWaldenstrom's macroglobulinemiaの重複例
永沼綾子, 菊地優子, 長谷山佳菜, 小野杏子, 小林毅, 小林則子, 北舘明宏, 亀岡吉弘, 高橋直人, 廣川誠
日本検査血液学会雑誌 18 ( 学術集会 ) S182 - S182 2017.06
-
移植非適応未治療多発性骨髄腫患者に対するLd療法およびレナリドミドの至適血漿中濃度の検討
小林 敬宏, 三浦 昌朋, 新岡 丈典, 鐙屋 舞子, 大八木 秀明, 篠原 良徳, 茂木 睦仁, 黒木 淳, 西成 民夫, 川端 良成, 北林 淳, 道下 吉広, 池田 翔, 志田 青慈, 吉岡 智子, 高橋 直人
International Journal of Myeloma ( 日本骨髄腫学会 ) 7 ( 1 ) 71 - 71 2017.04
-
維持透析併用で自家移植を行い透析離脱できた多発性骨髄腫
荒井 岳史, 池田 翔, 新井 郷史, 今泉 ちひろ, 山下 鷹也, 北舘 明宏, 小林 五十鈴, 小林 敬宏, 奈良 美保, 郭 永梅, 鵜生川 久美, 渡部 敦, 藤島 直仁, 藤島 眞澄, 吉岡 智子, 亀岡 吉弘, 田川 博之, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 58 ( 4 ) 401 - 402 2017.04
-
骨髄腫細胞において低酸素で上昇するコーディング・ノンコーディング遺伝子の網羅的探索とその機能解析
池田翔, 北舘明宏, 阿部史人, 小林敬宏, 高橋直人, 田川博之
International Journal of Myeloma (Web) 7 ( 1 ) 54 - 54 2017.04
-
Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.
Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H, Tohoku Hematology Forum
International Journal of Hematology 105 ( 5 ) 606 - 613 2017.02
-
Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.
Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y, Tohoku Hematology Forum
Leuk Lymphoma. 58 ( 6 ) 1509 - 1511 2017.01
-
Teshima K, Ohyagi H, Kume M, Takahashi S, Saito M, Takahashi N
[Rinsho ketsueki] The Japanese journal of clinical hematology ( The Japanese Society of Hematology ) 58 ( 11 ) 2227 - 2231 2017
<p>A 79-year-old male patient presented with systemic lymphadenopathy. A lymph node biopsy revealed effacement of the normal nodal architecture with diffuse proliferation of medium-sized atypical lymphoid cells. Southern blot analyses demonstrated rearrangement of the T-cell receptor gene but not the immunoglobulin heavy chain gene. He was diagnosed with CD20-positive peripheral T-cell lymphoma (PTCL), NOS. Although he achieved partial remission after six cycles of R-CHOP, he relapse occurred after 2 months. CD20-negative conversion was confirmed in the lymph node, which was positive for CCR4, and the skin at the time of relapse. The patient received the GDP regimen as salvage therapy with the addition of vorinostat for skin involvement; however, he failed to respond, and the disease systemically progressed. Furthermore, he also exhibited progression in the skin after stopping vorinostat due to hematologic toxicity. A lymph node biopsy at progression revealed CD20 re-expression by immunohistochemistry. At progression, the patient received mogamulizumab but failed to respond, and he died owing to disease progression 8 months after relapse. In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.</p>
-
FUJISHIMA Masumi, TAKAHASHI Naoto, FUJISHIMA Naohito, KITADATE Akihiro, GUO Yongmei, WATANABE Atsushi, UBUKAWA Kumi, NARA Miho, YOSHIOKA Tomoko, KAMEOKA Yoshihiro
Rinsho Ketsueki ( The Japanese Society of Hematology ) 58 ( 7 ) 743 - 748 2017
<p>A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.</p>
-
TAFRO Syndrome with Bilateral Adrenal Hemorrhage
Ito F, Kameoka Y, Nara M, Ubukawa K, Fujishima M, Yoshioka T, Fujishima N, Takahashi N
Nihon Naika Gakkai Zasshi. 106 ( 2 ) 288 - 294 2017
-
TAFRO Syndrome with Bilateral Adrenal Hemorrhage
Ito Fumiko, Kameoka Yoshihiro, Nara Miho, Ubukawa Kumi, Fujishima Masumi, Yoshioka Tomoko, Fujishima Naohito, Takahashi Naoto
Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine ) 106 ( 2 ) 288 - 294 2017